← Browse by Condition
Medical Condition

carcinoma non small cell lung

Total Trials
14
Recruiting Now
14
Trial Phases
Phase 2, Phase 1, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for carcinoma non small cell lung sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — carcinoma non small cell lung Clinical Trials

How many clinical trials are currently recruiting for carcinoma non small cell lung?
ClinicalMetric currently tracks 14 actively recruiting clinical trials for carcinoma non small cell lung, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 14. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for carcinoma non small cell lung?
carcinoma non small cell lung research spans Phase 1 (4 trials), Phase 2 (7 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a carcinoma non small cell lung clinical trial?
Eligibility criteria for carcinoma non small cell lung trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
4
Phase 2
7
Phase 3
1
Top Sponsors
Merck Sharp & Dohme LLC 2 trials
Janssen Research & Development, LLC 2 trials
Nantes University Hospital 1 trial
Hackensack Meridian Health 1 trial
US Oncology Research 1 trial

Recruiting Clinical Trials

NCT06481813
Recruiting
Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients
Enrollment
730 pts
Location
France
Sponsor
Nantes University Hospital
View Trial →
NCT05715229 Phase 2
Recruiting
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
Enrollment
108 pts
Location
United States
Sponsor
Hackensack Meridian Health
View Trial →
NCT05885698
Recruiting
MYLUNG Consortium Part 3: Observational Study
Enrollment
7,500 pts
Location
United States
Sponsor
US Oncology Research
View Trial →
NCT04165798
Recruiting
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
Enrollment
1,065 pts
Location
United States, Hunga...
Sponsor
Merck Sharp & Dohme LLC
View Trial →
NCT06131840 Phase 1
Recruiting
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Enrollment
914 pts
Location
United States, Canad...
Sponsor
Seagen, a wholly owned subsidi...
View Trial →
NCT06862869
Recruiting
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
Enrollment
800 pts
Location
China
Sponsor
Hoffmann-La Roche
View Trial →
NCT06079970
Recruiting
Confocal Laser Endomicroscopy VERification
Enrollment
208 pts
Location
United States, Austr...
Sponsor
Amsterdam University Medical C...
View Trial →
NCT04486833 Phase 1, Phase 2
Recruiting
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Enrollment
158 pts
Location
United States
Sponsor
Genprex, Inc.
View Trial →
NCT05498428 Phase 2
Recruiting
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Enrollment
520 pts
Location
United States, Brazi...
Sponsor
Janssen Research & Development...
View Trial →
NCT07586202 Phase 2
Recruiting
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
Enrollment
68 pts
Location
United States, Canad...
Sponsor
Janssen Research & Development...
View Trial →
NCT04165070 Phase 1, Phase 2
Recruiting
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Enrollment
450 pts
Location
United States, Hunga...
Sponsor
Merck Sharp & Dohme LLC
View Trial →
NCT07339176 Phase 1, Phase 2
Recruiting
Intratumoral N17350 in Advanced Solid Tumors
Enrollment
275 pts
Location
United States, Austr...
Sponsor
Onchilles Pharma Inc
View Trial →
NCT05487391 Phase 3
Recruiting
A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.
Enrollment
632 pts
Location
China
Sponsor
Qilu Pharmaceutical Co., Ltd.
View Trial →
NCT06627738 Phase 2
Recruiting
Locally Advanced NSCLC Treated With Radiochemotherapy: Phase 2 Study on the Value of a Stereotactic Boost
Enrollment
42 pts
Location
France
Sponsor
Centre Antoine Lacassagne
View Trial →

Related Conditions

lung cancer (2) small cell lung carcinoma (2) metastatic lung cancer (1) colorectal neoplasms (1) stomach neoplasms (1) pancreatic ductal adenocarcinoma (1) gastroesophageal junction adenocarcinoma (1) lung neoplasm malignant (1) neoplasm of lung (1) neoplasms solid tumor (1) breast neoplasms triple negative (1) squamous cell carcinoma of skin (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology